Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelsey Linstrum

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Infectious Diseases|November 16, 2023
Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised IndividualsGhady Haidar, Jacob C Hodges, Andrew Bilderback, et al.
Trials|May 26, 2021
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
American Journal of Respiratory and Critical Care Medicine|March 29, 2022
CD4<sup>+</sup> T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-α/Tumor Necrosis Factor Receptor 1-DependentIulia Popescu, Mark E Snyder, Carlo J Iasella, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 18, 2022
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)Ghady Haidar, Mounzer Agha, Andrew Bilderback, et al.
Contemporary Clinical Trials|June 13, 2022
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, J Ryan Bariola, Tami E Minnier, et al.
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Intensive Care Medicine|July 12, 2021
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M Arabi, Anthony C Gordon, Lennie P G Derde, et al.
JAMA|October 4, 2021
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial, Lise J Estcourt, Alexis F Turgeon, et al.
The New England Journal of Medicine|August 5, 2021
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19, , , et al.
The New England Journal of Medicine|August 5, 2021
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19, , , et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Infectious Diseases|November 16, 2023
Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised IndividualsGhady Haidar, Jacob C Hodges, Andrew Bilderback, et al.
Trials|May 26, 2021
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
American Journal of Respiratory and Critical Care Medicine|March 29, 2022
CD4<sup>+</sup> T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-α/Tumor Necrosis Factor Receptor 1-DependentIulia Popescu, Mark E Snyder, Carlo J Iasella, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 18, 2022
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)Ghady Haidar, Mounzer Agha, Andrew Bilderback, et al.
Contemporary Clinical Trials|June 13, 2022
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, J Ryan Bariola, Tami E Minnier, et al.
JAMA Network Open|July 14, 2022
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness TrialDavid T Huang, Erin K McCreary, J Ryan Bariola, et al.
Intensive Care Medicine|July 12, 2021
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M Arabi, Anthony C Gordon, Lennie P G Derde, et al.
JAMA|October 4, 2021
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial, Lise J Estcourt, Alexis F Turgeon, et al.
The New England Journal of Medicine|August 5, 2021
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19, , , et al.
The New England Journal of Medicine|August 5, 2021
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19, , , et al.
Pageof 3